Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON MATTHEW HAFRON

Allopathic & Osteopathic Physicians Urology

NPI
1255483277
CMS profile
283707
Location
WEST BLOOMFIELD, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$67,135.77

143 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON MATTHEW HAFRON

NPI 1255483277 · CMS profile ID 283707

Allopathic & Osteopathic Physicians / Urology

WEST BLOOMFIELD, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255483277?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON MATTHEW HAFRON, NPI 1255483277, CMS profile ID 283707. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255483277?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JASON MATTHEW HAFRON, NPI 1255483277, CMS profile ID 283707. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255483277?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JASON MATTHEW HAFRON, NPI 1255483277, CMS profile ID 283707, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 143 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1255483277?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

143 matching records · $67,135.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 143 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 143.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $24.1209/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048695871 CMS
Astellas Pharma US Inc $6.6709/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034485503 CMS
Ferring Pharmaceuticals Inc. $20.2309/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044160261 CMS
Verity Pharmaceuticals Inc. $14.1408/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019428103 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.4008/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000855829 CMS
Blue Earth Diagnostics Limited $900.0008/23/2023 Honoraria No dispute reported Delay: No
Change: CHANGED
06/30/2026 1059986383 CMS
Sumitomo Pharma America, Inc. $15.1508/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030919973 CMS
Tolmar, Inc. $1,600.0008/17/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056958455 CMS
Dendreon Pharmaceuticals LLC $34.1908/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060285437 CMS
Myriad Genetic Laboratories, Inc. $5.1108/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776315 CMS
Boston Scientific Corporation $43.7808/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021953661 CMS
Boston Scientific Corporation $60.8808/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022484209 CMS
Janssen Biotech, Inc. $36.4308/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988213863 CMS
Myriad Genetic Laboratories, Inc. $750.0007/31/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776311 CMS
Myriad Genetic Laboratories, Inc. $250.0007/28/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776307 CMS
Teleflex LLC $17.1707/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027401715 CMS
Teleflex LLC $97.1507/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027418425 CMS
Astellas Pharma US Inc $16.6307/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034298045 CMS
Myriad Genetic Laboratories, Inc. $500.0007/18/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776305 CMS
PFIZER INC. $7.4407/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049394659 CMS
Verity Pharmaceuticals Inc. $14.4207/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019428055 CMS
PROCEPT BioRobotics Corporation $1,150.0007/07/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057634451 CMS
Blue Earth Diagnostics Limited $20.7206/30/2023 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 1059986277 CMS
PROCEPT BioRobotics Corporation $121.4006/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057607625 CMS
UroGen Pharma, Inc. $26.5006/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038604769 CMS
Myriad Genetic Laboratories, Inc. $1,125.0006/24/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776299 CMS
UroGen Pharma, Inc. $5.4206/23/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038601135 CMS
Myriad Genetic Laboratories, Inc. $47.0006/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776295 CMS
Myriad Genetic Laboratories, Inc. $4,000.0006/20/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776277 CMS
Myriad Genetic Laboratories, Inc. $40.2106/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776281 CMS
Myriad Genetic Laboratories, Inc. $299.0006/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776285 CMS
Myriad Genetic Laboratories, Inc. $93.9406/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776289 CMS
Myriad Genetic Laboratories, Inc. $52.0306/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776291 CMS
Janssen Biotech, Inc. $17.8306/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988213983 CMS
Merck Sharp & Dohme LLC $25.1506/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048695875 CMS
Myriad Genetic Laboratories, Inc. $250.0006/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776273 CMS
Progenics Pharmaceuticals, Inc. $975.0006/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112887 CMS
Progenics Pharmaceuticals, Inc. $21.6306/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991110161 CMS
Sumitomo Pharma America, Inc. $15.0706/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1030919981 CMS
Verity Pharmaceuticals Inc. $10.1506/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019428095 CMS
Progenics Pharmaceuticals, Inc. $5.0006/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991110169 CMS
Dendreon Pharmaceuticals LLC $33.0206/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060285435 CMS
Janssen Biotech, Inc. $20.9706/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988213993 CMS
Tolmar, Inc. $21.5706/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056963453 CMS
Myriad Genetic Laboratories, Inc. $363.0006/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776269 CMS
Myriad Genetic Laboratories, Inc. $250.0005/31/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776265 CMS
Dendreon Pharmaceuticals LLC $1,350.0005/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060285433 CMS
Myriad Genetic Laboratories, Inc. $10.8905/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059776261 CMS
Janssen Biotech, Inc. $1,100.0005/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988213944 CMS
Janssen Global Services, LLC $337.5005/12/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988596955 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $98,852.82 232
PY2020 $56,821.18 66
PY2021 $64,519.42 87
PY2022 $72,789.55 131
PY2023 $67,135.77 143
PY2024 $47,075.53 116
PY2025 $83,096.95 146

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $7,088.13 4
PY2025 Principal investigator $1,962,351.80 110
PY2024 Principal investigator $2,014,650.72 126
PY2023 Principal investigator $2,215,528.56 112
PY2022 Principal investigator $1,283,508.84 91
PY2021 Principal investigator $995,280.34 100
PY2020 Principal investigator $566,400.52 95
PY2019 Principal investigator $356,842.38 147

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

114 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $37,491.28 12/31/2025 Non-covered Recipient Entity
Michigan Institute of Urology
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232927063
Principal investigator 1 Merck Sharp & Dohme LLC $2,170.95 12/31/2025 Non-covered Recipient Entity
Michigan Institute of Urology
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232927065
Principal investigator 1 Merck Sharp & Dohme LLC $358,623.65 12/29/2025 Non-covered Recipient Entity
Michigan Institute of Urology
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232927015
Principal investigator 1 Janssen Research & Development, LLC $8,066.00 12/26/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361789
Principal investigator 1 Sumitomo Pharma America, Inc. $120.00 12/22/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657682
Principal investigator 1 Janssen Research & Development, LLC $554.00 12/15/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361811
Principal investigator 1 Janssen Research & Development, LLC $21,437.00 12/15/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361931
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 12/10/2025 Non-covered Recipient Entity
Michigan Inst Of Uro PC
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175234326
Principal investigator 1 Janssen Research & Development, LLC $4,033.00 12/01/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361774
Principal investigator 1 Janssen Research & Development, LLC $456.00 11/24/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175234046
Principal investigator 1 Janssen Research & Development, LLC $1,020.40 11/24/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361748
Principal investigator 1 Janssen Research & Development, LLC $1,831.80 11/24/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361884
Principal investigator 1 Janssen Research & Development, LLC $8,066.00 11/07/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361723
Principal investigator 1 Janssen Research & Development, LLC $30,858.00 11/03/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361668
Principal investigator 1 Janssen Research & Development, LLC $15,895.00 11/03/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361781
Principal investigator 1 PFIZER INC. $4,042.00 11/01/2025 Non-covered Recipient Entity
Michigan Institute of Urology PC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228728503
Principal investigator 1 Janssen Research & Development, LLC $2,442.40 10/27/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361714
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $21,212.55 10/15/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol No dispute reported 06/30/2026 1254646854
Principal investigator 1 Janssen Research & Development, LLC $12,099.00 10/06/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361836
Principal investigator 1 Janssen Research & Development, LLC $456.00 10/02/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175234074
Principal investigator 1 PFIZER INC. $7,325.25 09/23/2025 Non-covered Recipient Entity
Michigan Institute of Urology PC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228770000
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $3,349.35 09/22/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol No dispute reported 06/30/2026 1254646852
Principal investigator 1 Janssen Research & Development, LLC $610.60 09/19/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361767
Principal investigator 1 Janssen Research & Development, LLC $270.00 09/19/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175361908
Principal investigator 1 Janssen Research & Development, LLC $16,465.00 09/15/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361562
Principal investigator 1 Janssen Research & Development, LLC $300.00 09/15/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361661
Principal investigator 1 Janssen Research & Development, LLC $15,172.00 09/15/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361696
Principal investigator 1 Organon Llc $32,623.01 09/10/2025 Non-covered Recipient Entity
Michigan Institute of Urology
3475-676 No dispute reported 06/30/2026 1173042150
Principal investigator 1 Organon Llc $11,770.38 09/10/2025 Non-covered Recipient Entity
Michigan Institute of Urology
3475-676 No dispute reported 06/30/2026 1173042324
Principal investigator 1 Organon Llc $12,570.38 09/10/2025 Non-covered Recipient Entity
Michigan Institute of Urology
3475-676 No dispute reported 06/30/2026 1173042326
Principal investigator 1 Organon Llc $1,901.00 09/10/2025 Non-covered Recipient Entity
Michigan Institute of Urology
3475-676 No dispute reported 06/30/2026 1173042614
Principal investigator 1 Janssen Research & Development, LLC $12,099.00 09/05/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361797
Principal investigator 1 Organon Llc $200.00 09/03/2025 Non-covered Recipient Entity
Michigan Institute of Urology
3475-676 No dispute reported 06/30/2026 1173042420
Principal investigator 1 Organon Llc $135.00 09/03/2025 Non-covered Recipient Entity
Michigan Institute of Urology
3475-676 No dispute reported 06/30/2026 1173042612
Principal investigator 1 Janssen Research & Development, LLC $208.00 08/25/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361631
Principal investigator 1 Janssen Research & Development, LLC $150.00 08/21/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361731
Principal investigator 1 PFIZER INC. $9,667.55 08/09/2025 Non-covered Recipient Entity
Michigan Institute of Urology PC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228767221
Principal investigator 1 Dendreon Pharmaceuticals LLC $7,000.00 08/08/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
PROVONE STUDY No dispute reported 06/30/2026 1247892332
Principal investigator 1 Dendreon Pharmaceuticals LLC $556.25 08/08/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
PROVONE STUDY No dispute reported 06/30/2026 1247892335
Principal investigator 1 Janssen Research & Development, LLC $85.00 08/04/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361653
Principal investigator 1 Janssen Research & Development, LLC $17,007.00 07/25/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361570
Principal investigator 1 Janssen Research & Development, LLC $240.00 07/25/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361675
Principal investigator 1 Janssen Research & Development, LLC $17,521.00 07/25/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361818
Principal investigator 1 Janssen Research & Development, LLC $610.60 07/24/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361862
Principal investigator 1 Janssen Research & Development, LLC $6,600.00 07/17/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair HRR Gene Mutated Metastatic Castration Sensitive Prostate Cancer mCSPC No dispute reported 06/30/2026 1175361604
Principal investigator 1 Janssen Research & Development, LLC $780.00 07/16/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175234082
Principal investigator 1 Janssen Research & Development, LLC $16,132.00 07/07/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361690
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $20,096.10 07/01/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol No dispute reported 06/30/2026 1249804093
Principal investigator 1 Janssen Research & Development, LLC $456.00 06/25/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175234060
Principal investigator 1 Janssen Research & Development, LLC $19,088.00 06/23/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361897
Principal investigator 1 Sumitomo Pharma America, Inc. $350.00 06/18/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176636389
Principal investigator 1 Janssen Research & Development, LLC $384.00 06/16/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175234025
Principal investigator 1 Janssen Research & Development, LLC $61.00 06/16/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361623
Principal investigator 1 PFIZER INC. $8,792.75 06/13/2025 Non-covered Recipient Entity
Michigan Institute of Urology PC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228786231
Principal investigator 1 Janssen Research & Development, LLC $8,066.00 06/09/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361762
Recipient Dendreon Pharmaceuticals LLC $25.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891351
Recipient Dendreon Pharmaceuticals LLC $1,802.50 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891354
Recipient Dendreon Pharmaceuticals LLC $2,550.00 06/05/2025 Covered Recipient Physician PROVONE STUDY No dispute reported 06/30/2026 1247891359
Principal investigator 1 Dendreon Pharmaceuticals LLC $50.00 06/05/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
ProvONE No dispute reported 06/30/2026 1247892173
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,802.50 06/05/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
ProvONE No dispute reported 06/30/2026 1247892181
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,550.00 06/05/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
ProvONE No dispute reported 06/30/2026 1247892185
Recipient Novartis Pharmaceuticals Corporation $2,710.63 06/02/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190293444
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $12,280.95 05/28/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol No dispute reported 06/30/2026 1249804005
Principal investigator 1 Janssen Research & Development, LLC $1,920.00 05/19/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175234040
Principal investigator 1 Janssen Research & Development, LLC $23,877.00 05/19/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361755
Principal investigator 1 Janssen Research & Development, LLC $180.00 05/19/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361917
Principal investigator 1 Merck Sharp & Dohme LLC $946.31 05/19/2025 Non-covered Recipient Entity
Michigan Institute of Urology, PC
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with Pembrolizumab Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma KEYVIBE-010 No dispute reported 06/30/2026 1232936484
Principal investigator 1 Janssen Research & Development, LLC $25,204.00 05/12/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361845
Principal investigator 1 Sumitomo Pharma America, Inc. $2,189.40 05/07/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176634394
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $8,931.60 04/30/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol No dispute reported 06/30/2026 1249803932
Principal investigator 1 Janssen Research & Development, LLC $4,033.00 04/28/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361938
Principal investigator 1 Janssen Research & Development, LLC $610.60 04/28/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361960
Principal investigator 1 PFIZER INC. $218.70 04/26/2025 Non-covered Recipient Entity
Michigan Institute of Urology PC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228780239
Principal investigator 1 Janssen Research & Development, LLC $6,576.00 04/25/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361683
Principal investigator 1 PFIZER INC. $874.80 04/15/2025 Non-covered Recipient Entity
Michigan Institute of Urology PC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228781103
Principal investigator 1 Janssen Research & Development, LLC $9,421.00 04/11/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361868
Principal investigator 1 Janssen Research & Development, LLC $6,104.40 04/11/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361968
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $10,048.05 04/09/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol No dispute reported 06/30/2026 1249803884
Principal investigator 1 Sumitomo Pharma America, Inc. $1,904.00 04/09/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632960
Principal investigator 1 Sumitomo Pharma America, Inc. $2,159.40 04/09/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX No dispute reported 06/30/2026 1176632964
Principal investigator 1 Janssen Research & Development, LLC $12,099.00 04/03/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361739
Principal investigator 1 Ferring Pharmaceuticals AS $21,772.00 03/20/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) No dispute reported 06/30/2026 1242060279
Principal investigator 1 Janssen Research & Development, LLC $912.00 03/17/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175234098
Principal investigator 1 Janssen Research & Development, LLC $270.00 03/17/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361829
Principal investigator 1 PFIZER INC. $160.00 03/13/2025 Non-covered Recipient Entity
Michigan Institute of Urology PC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228798038
Principal investigator 1 Janssen Research & Development, LLC $4,033.00 03/07/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361645
Principal investigator 1 Janssen Research & Development, LLC $107.50 03/07/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361948
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $16,390.80 03/05/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol No dispute reported 06/30/2026 1249803700
Principal investigator 1 Sumitomo Pharma America, Inc. $4,500.00 03/05/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176630282
Principal investigator 1 Merck Sharp & Dohme LLC $533.26 03/03/2025 Non-covered Recipient Entity
Michigan Institute of Urology, PC
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232927017
Principal investigator 1 Dendreon Pharmaceuticals LLC $2,150.00 02/26/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
PROVONE STUDY No dispute reported 06/30/2026 1247891755
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,550.00 02/26/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
PROVONE STUDY No dispute reported 06/30/2026 1247891759
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $11,164.50 02/26/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol No dispute reported 06/30/2026 1254646850
Principal investigator 1 Janssen Research & Development, LLC $3,053.00 02/24/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361597
Principal investigator 1 Janssen Research & Development, LLC $38.50 02/17/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361639
Principal investigator 1 Janssen Research & Development, LLC $20,732.00 02/17/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361875
Principal investigator 1 Janssen Research & Development, LLC $485.00 02/17/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361955
Principal investigator 1 Janssen Research & Development, LLC $900.00 02/13/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175234068
Principal investigator 1 PFIZER INC. $12,714.70 02/13/2025 Non-covered Recipient Entity
Michigan Institute of Urology PC
A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL THREE PARALLELARM STUDY OF PF06801591 AN ANTIPD1 ANTIBODY IN COMBINATION WITH BACILLUS CALMETTEGUERIN BCG INDUCTION WITH OR WITHOUT BCG MAINTENANCE VERSUS BCG INDUCTION AND MAINTENANCE IN PARTICIPANTS WITH HIGHRISK BCGNAIVE NONMUSCLE INVASIVE BLADDER CANCER No dispute reported 06/30/2026 1228769142
Principal investigator 1 Janssen Research & Development, LLC $4,874.00 02/11/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) No dispute reported 06/30/2026 1175234033
Principal investigator 1 Janssen Research & Development, LLC $17,516.00 02/10/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361613
Principal investigator 1 Janssen Research & Development, LLC $1,831.80 02/03/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy No dispute reported 06/30/2026 1175361705
Principal investigator 1 AstraZeneca Pharmaceuticals LP $490,611.58 01/29/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185551587
Principal investigator 1 Ortho-Clinical Diagnostics, Inc. $15,630.30 01/29/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
VITROS Immunodiagnostic Products Free PSA III Assay Aid in Distinction Intended Use Collection Protocol No dispute reported 06/30/2026 1249803496
Principal investigator 1 Sumitomo Pharma America, Inc. $6,666.00 01/29/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176624976
Principal investigator 1 Janssen Research & Development, LLC $4,134.00 01/20/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361580
Principal investigator 1 Janssen Research & Development, LLC $1,034.00 01/20/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361586
Principal investigator 1 Janssen Research & Development, LLC $16,291.00 01/20/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361802
Principal investigator 1 Janssen Research & Development, LLC $16,291.00 01/20/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361854
Principal investigator 1 Janssen Research & Development, LLC $75,974.00 01/20/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361890
Principal investigator 1 Janssen Research & Development, LLC $10,670.00 01/20/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY
A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) No dispute reported 06/30/2026 1175361922
Principal investigator 1 Janssen Research & Development, LLC $4,400.00 01/10/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175234053
Principal investigator 1 Janssen Research & Development, LLC $1,860.00 01/10/2025 Non-covered Recipient Entity
Michigan Inst Of Uro
A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy No dispute reported 06/30/2026 1175234090
Principal investigator 1 AstraZeneca Pharmaceuticals LP $277,103.90 01/03/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE OF UROLOGY PC
a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco No dispute reported 06/30/2026 1185551589